~ Dietary Supplements Attacked by the Media - References
1. What's Next for Arthritis Sufferers: Doctors Hold Out Hope for Supplements. The Wall Street Journal; Feb 28, 2006; D.1 Available at: www.wsj.com Accessed February 2006
2. Available at: http://www.washingtonpost.com/wp-dyn/content/article/2006/02/07/AR2006020701681.html Accessed February 2006
3. Howard BV , Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
JAMA. 2006 Feb 8;295(6):655-66.
4. Beresford SA , Johnson KC, Ritenbaugh C, et al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
JAMA. 2006 Feb 8;295(6):643-54.
5. Prentice RL , Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
JAMA. 2006 Feb 8;295(6):629-42.
6. Available at: www.healthy.net/asp/templates/news.asp?Id=5713 Accessed March 2006
7. de Roos NM, Bots ML, Katan MB. Replacement of dietary saturated fatty acids by trans fatty acids lowers serum HDL cholesterol and impairs endothelial function in healthy men and women. Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1233-7.
8. Oomen CM, Ocke MC, Feskens EJ, van Erp-Baart MA, Kok FJ, Kromhout D. Association between trans fatty acid intake and 10-year risk of coronary heart disease in the Zutphen Elderly Study: a prospective population-based study. Lancet. 2001 Mar 10;357(9258):746-51.
9. Kris-Etherton, PM, Taylor, DS, Yu-Poth, S, et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr. 2000 Jan;71(1 Suppl):179S-88S.
10. Mensink RP, Zock PL, Katan MB, Hornstra G. Effect of dietary cis and trans fatty acids on serum lipoprotein[a] levels in humans. J Lipid Res. 1992 Oct;33(10):1493-501.
11. Katan MB, Mensink R, Van Tol A, Zock PL. Dietary trans fatty acids and their impact on plasma lipoproteins. Can J Cardiol . 1995 Oct;11 Suppl G:36G-38G.
12. Trichopoulou A, Orfanos P, Norat T, et al. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. BMJ. 2005 Apr 30;330(7498):991.
13. Visalia F, Bogani P, Grande S, Galli C. Mediterranean food and health: building human evidence. J Physiol Pharmacol. 2005 Mar;56 Suppl 1:37-49.
14. Trichopoulou A, Bania C, Trichopoulou D. Mediterranean diet and survival among patients with coronary heart disease in Greece. Arch Intern Med. 2005 Apr 25;165(8):929-35.
15. Miles EA, Zoubouli P, Calder PC. Differential anti-inflammatory effects of phenolic compounds from extra virgin olive oil identified in human whole blood cultures. Nutrition. 2005 Mar;21(3):389-94.
16. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004 Nov;6(6):461-7.
17. Marrugat J, Covas MI, Fito M, et al. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation—a randomized controlled trial. Eur J Nutr. 2004 Jun;43(3):140-7.
18. O’Dowd Y, Driss F, Dang PM, et al. Antioxidant effect of hydroxytyrosol, a polyphenol from olive oil: scavenging of hydrogen peroxide but not superoxide anion produced by human neutrophils. Biochem Pharmacol. 2004 Nov 15;68(10):2003-8.
19. Masella R, Vari R, D’Archivio M, et al. Extra virgin olive oil biophenols inhibit cell-mediated oxidation of LDL by increasing the mRNA transcription of glutathione-related enzymes. J Nutr. 2004 Apr;134(4):785-91.
20. Roland I, De Leval X, Evrard B, Pirotte B, Dogne JM, Delattre L. Modulation of the arachidonic cascade with omega3 fatty acids or analogues: potential therapeutic benefits. Mini Rev Med Chem. 2004 Aug;4(6):659-68.
21. Vissers MN, Zock PL, Katan MB. Bioavailability and antioxidant effects of olive oil phenols in humans: a review. Eur J Clin Nutr. 2004 Jun;58(6):955-65.
22. Mateos R, Dominguez MM, Espartero JL, Cert A. Antioxidant effect of phenolic compounds, alpha-tocopherol, and other minor components in virgin olive oil. J Agric Food Chem. 2003 Nov 19;51(24):7170-5.
23. Lavelli V. Comparison of the antioxidant activities of extra virgin olive oils. J Agric Food Chem. 2002 Dec 18;50(26):7704-8.
24. Fito M, Gimeno E, Covas MI, et al. Postprandial and short-term effects of dietary virgin olive oil on oxidant/antioxidant status. Lipids. 2002 Mar;37(3):245-51.
25. Gimeno E, Fito M, Lamuela-Raventos RM, et al. Effect of ingestion of virgin olive oil on human low-density lipoprotein composition. Eur J Clin Nutr. 2002 Feb;56(2):114-20.
26. Wiseman SA, Tijburg LB, van de Put FH. Olive oil phenolics protect LDL and spare vitamin E in the hamster. Lipids. 2002 Nov;37(11):1053-7.
27. Romero C, Brenes M, Garcia P, Garrido A. Hydroxytyrosol 4-beta-D-glucoside, an important phenolic compound in olive fruits and derived products. J Agric Food Chem. 2002 Jun 19;50(13):3835-9.
28. Kris-Etherton PM, Hecker KD, Bonanome A, et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med. 2002 Dec 30;113 Suppl 9B:71S-88S.
29. Simopoulos AP. The Mediterranean diets: What is so special about the diet of Greece? The scientific evidence. J Nutr. 2001 Nov;131(11 Suppl):3065S-73S.
30. Vissers MN, Zock PL, Leenen R, Roodenburg AJ, van Putte KP, Katan MB. Effect of consumption of phenols from olives and extra virgin olive oil on LDL oxidizability in healthy humans. Free Radic Res. 2001 Nov;35(5):619-29.
31. de la Puerta R, Martinez Dominguez ME, Ruiz-Gutierrez V, Flavill JA, Hoult JR. Effects of virgin olive oil phenolics on scavenging of reactive nitrogen species and upon nitrergic neurotransmission. Life Sci. 2001 Jul 27; 69(10):1213-22.
32. Masella R, Giovannini C, Vari R, et al. Effects of dietary virgin olive oil phenols on low density lipoprotein oxidation in hyperlipidemic patients. Lipids. 2001 Nov;36(11):1195-202.
33. Covas MI, Fito M, Lamuela-Raventos RM, Sebastia N, de la Torre-Boronat C, Marrugat J. Virgin olive oil phenolic compounds: binding to human low density lipoprotein (LDL) and effect on LDL oxidation. Int J Clin Pharmacol Res. 2000 20(3-4):49-54.
34. Owen RW, Giacosa A, Hull WE, Haubner R, Spiegelhalder B, Bartsch H. The antioxidant/anticancer potential of phenolic compounds isolated from olive oil. Eur J Cancer. 2000 Jun;36(10):1235-47.
35. Visioli F, Bellomo G, Galli C. Free radical-scavenging properties of olive oil polyphenols. Biochem Biophys Res Commun. 1998 Jun 9;247(1):60-4.
36. Lucas EA, Lightfoot SA, Hammond LJ, et al. Flaxseed reduces plasma cholesterol and atherosclerotic lesion formation in ovariectomized Golden Syrian hamsters. Atherosclerosis. 2004 Apr;173(2):223-9.
37. Dabrosin C, Chen J, Wang L, Thompson LU. Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett. 2002 Nov 8;185(1):31-7.
38. Platt R. Current concepts in optimum nutrition for cardiovascular disease. Prev Cardiol. 2000 Spring;3(2):83-7.
39. Prasad K. Flaxseed: a source of hypocholesterolemic and antiatherogenic agents. Drug News Perspect. 2000 Mar;13(2):99-104.
40. Jenkins DJ, Kendall CW, Vidgen E, et al. Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Am J Clin Nutr. 1999 Mar;69(3):395-402.
41. Prasad K, Mantha SV, Muir AD, Westcott ND. Reduction of hypercholesterolemic atherosclerosis by CDC-flaxseed with very low alpha-linolenic acid. Atherosclerosis. 1998 Feb;136(2):367-75.
42. Arterial compliance in obese subjects is improved with dietary plant n-3 fatty acid from flaxseed oil despite increased LDL oxidizability. Arterioscler Thromb Vasc Biol. 1997 Jun;17(6): 1163-70.
43. Bierenbaum ML, Reichstein R, Watkins TR. Reducing atherogenic risk in hyperlipemic humans with flax seed supplementation: a preliminary report. J Am Coll Nutr. 1993 Oct;12(5):501-4.
44. AHRQ Evidence Reports Confirm that Fish Oil Helps Fight Heart Disease. Press Release, April 22, 2004. Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://www.ahrq.gov/news/press/pr2004/omega3pr.htm Accessed March 2006
45. Calder, PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids. 2003 Apr;38(4):343-52.
46. Mayer, K, Merfels, M, Muhly-Reinholz, M, et al. Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am J Physiol Heart Circ Physiol. 2002 Aug;283(2):H811-8.
47. Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A. Fatty fish consumption and risk of prostate cancer. Lancet. 2001 Jun 2;357(9270):1764-66.
48. Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, Bagga D. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology. 2001 Aug;58(2):283-8.
49. Curtis CL, Hughes CE, Flannery CR, Little CB, Harwood JL, Caterson B. n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J Biol Chem. 2000 Jan 14;275(2):721-4.
50. Andrioli G, Carletto A, Guarini P, et al. Differential effects of dietary supplementation with fish oil or soy lecithin on human platelet adhesion. Thromb Haemost. 1999 Nov;82(5):1522-7.
51. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 1996 Jan;63(1):116-22.
52. Mori TA, Vandongen R, Beilin LJ, Burke V, Morris J, Ritchie J. Effects of varying dietary fat, fish, and fish oils on blood lipids in a randomized controlled trial in men at risk of heart disease. Am J Clin Nutr. 1994 May;59(5):1060-8.
53. Bartram HP, Gostner A, Scheppach W. Effects of fish oil on rectal cell proliferation, mucosal fatty acids, and prostaglandin E2 release in healthy subjects. Gastroenterology 1993 Nov;105(5):1317-22.
54. Espersen GT, Grunnet N, Lervang HH et al. Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids. Clin Rheumatol. 1992 Sep;11(3):393-5.
55. Li XL, Steiner M. Dose response of dietary fish oil supplementations on platelet adhesion. Arterioscler Thromb. 1991 Jan-Feb;11(1):39-46.
56. Sperling RI, Weinblatt M, Robin JL, et al. Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis Rheum 1987 Sep;30(9):988-97.
57. Jolly, CA, Muthukumar, A, Avula, CP, et al. Lifespan is prolonged in food-restricted auto-immune-prone [NZ-NZW] F mice fed a diet enriched with [n-3] fatty acids. Available at: http://www.nutrition.org/cgi/content/abstract/131/10/2753 Accessed March 2006.
58. Rebecca D. Jackson, M.D., Andrea Z. LaCroix, Ph.D., Margery Gass, M.D, et al. Calcium plus Vitamin D Supplementation and the Risk of Fractures.N Engl J Med. 2006 Feb 16;354(7):669-83.
59. Daniel O. Clegg, M.D., Domenic J. Reda, Ph.D., Crystal L. Harris, Pharm.D., et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. N Engl J Med. 2006 Feb 23;354(8):795-808.
60. Kolata G. “2 Arthritis Drugs Are Found to Be Ineffective.” NY Times article. 2006 Feb 23.
61. Available at: http://abcnews.go.com/Health/wireStory?id=1651917&CMP=OTC-RSSFeeds0312 Accessed March 2006.
62. Usha PR, Naidu MU. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest. 2004 Jun;24(6):353-63.
63. Ekmekcioglu C , Strauss-Blasche G, Holzer F, Marktl W. Effect of sulfur baths on antioxidative defense systems, peroxide concentrations and lipid levels in patients with degenerative osteoarthritis. Forsch Komplementarmed Klass Naturheilkd. 2002 Aug;9(4):216-20.
64. Parcell S . Sulfur in human nutrition and applications in medicine.Altern Med Rev. 2002 Feb;7(1):22-44.
65. Elkayam O, Ophir J, Brener S, Paran D, Wigler I, Efron D, Even-Paz Z, Politi Y, Yaron M. Immediate and delayed effects of treatment at the Dead Sea in patients with psoriatic arthritis. Rheumatol Int. 2000 19(3):77-82.
66. Jacob SW, Lawrence RM, Zucker M. The Miracle of MSM. New York: Berkley Books, 1999.
67. Sukenik S, Flusser D, Codish S, Abu-Shakra M. Balneotherapy at the Dead Sea area for knee osteoarthritis. Isr Med Assoc J. 1999 Oct;1(2):83-5.
68. Prater, G. MSM: the multi-purpose compound. Life Extension Magazine 1999 Sep;5(9):71-2. Ft. Lauderdale, FL: Life Extension Foundation.
69. Lawrence RM. Methylsulfonylmethane (MSM): a double-blind study of its use in degenerative arthritis. Int J Anti-Aging Med. 1998 1:50.
70. Bradley H , Gough A, Sokhi RS, Hassell A, Waring R, Emery P. Sulfate metabolism is abnormal in patients with rheumatoid arthritis. Confirmation by in vivo biochemical findings. J Rheumatol . 1994 Jul;21(7):1192-6.
71. Emery P , Bradley H, Gough A, Arthur V, Jubb R, Waring R. Increased prevalence of poor sulphoxidation in patients with rheumatoid arthritis: effect of changes in the acute phase response and second line drug treatment. Ann Rheum Dis. 1992 Mar;51(3):318-20.
72. Herschler RJ. Dietary and Pharmaceutical Uses of Methylsulfonylmethane and Compositions Comprising It. 1985 December 17; U.S. Patent 4,559,329.
73. Hardy ML, Coulter I, Morton SC, et al. S-Adenosylmethionine for treatment of depression, osteoarthritis and liver disease. Evid Rep Technol Assess (Summ) . 2003 Aug;(64):1-3.Available at: http://www.ahrq.gov/clinic/epcsums/samesum.htm Accessed March 2006.
74. Parcell S. Sulfur in human nutrition and applications in medicine. Altern Med Rev. 2002 Feb;7(1):22-44.
75. Konig B. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis. Am J Med. 1987 Nov 20;83(5A):89-94.
76. Maccagno A, Di Giorgio E, Caston O, Sagasta C. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med. 1987 Nov 20;83(5A):72-7.
77. Vetter G. Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis. Am J Med. 1987 Nov 20;83(5A):78-80.
78. Muller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis. Am J Med. 1987 Nov 20;83(5A):81-3.
79. Polli E, Cortellaro M, Parrini L, Tessari L, Cherie Ligniere G. Pharmacological and clinical aspects of S-adenosylmethionine (SAMe) in primary degenerative arthropathy (osteoarthrosis). Minerva Med. 1975 Dec 5;66(83):4443-59.
References continued . . .
Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.
While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.